CP
LGND icon

Covalent Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Covalent Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-140,402
Closed -$3.28M – 29
2013
Q2 		$3.28M Buy
+140,402
New +$2.53M 1.15% 24

Other funds holding LGND

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Covalent Partners's LGND Position: Q3 2013 in Review

Covalent Partners sold out of Ligand Pharmaceuticals (LGND) in Q3 2013, closing a stake of 140,402 shares — an estimated $3.28M sold.

Covalent Partners first reported a position in LGND in Q2 2013 and held it in 1 quarter. The position peaked at $3.28M in Q2 2013. 132 funds tracked by Wall St. Rank hold LGND as of Q3 2013.

  • Covalent Partners reported no remaining Ligand Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Covalent Partners sold 140,402 Ligand Pharmaceuticals shares in Q3 2013, an estimated $3.28M.
  • Covalent Partners first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Covalent Partners's Ligand Pharmaceuticals position peaked at $3.28M in Q2 2013.
  • 132 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2013.

Based on Covalent Partners's 13F filing for Q3 2013, filed 14 Nov 2013.